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Background: The effect of chemotherapy combined with monoclonal antibodies (mAbs) on the immune state of
the tumor environment remains unclear and controversial. The aim of this study is to examine the effect of
chemotherapy combined with cetuximab (C225, an anti-EGFR mAb) on the immune state of tumor environment,
and the correlation of that effect and the clinical efficacy.
Methods: Twelve patients with colorectal cancer, who received the treatment of chemotherapy combined with
C225, were enrolled in this study. The tumor specimen of the primary colorectal cancer before and after treatment
was obtained. The expression of a series of immune factors (TGF-β1, CD8, IL-2, TNF-α, and VEGF) was measured by
immunochemistry. The expression of these immune factors before and after treatment was compared by the
Wilcoxon signed-rank test. The correlation of the change of immune parameter expression after treatment and
clinical efficacy was examined by chi-square tests. The correlation of the expression of immune factors, clinical
efficacy, and treatment number was examined by the Spearman’s correlation analysis.
Results: There was no significant difference between the expression of TGF-β1 before and after the treatment
(P >0.05). The change of TGF-β1 expression after treatment significantly correlated negatively with clinical efficacy
(P = 0.05). As for CD8, IL-2, VEGF, and TNF-α, there were no significant differences between the expression before
and after the treatment (P >0.05), and the change of expression after treatment also did not correlate significantly
with clinical efficacy (P >0.05). The change of IL-2 expression after treatment significantly correlated negatively with
treatment number (correlation coefficient = -0.585, P = 0.046). The change of TGF-β1 expression after treatment
significantly correlated negatively with clinical efficacy (correlation coefficient = -0.684, P = 0.014). Before treatment,
the expression of TNF-α significantly correlated positively with the expression of IL-2 (correlation coefficient = 0.629,
P = 0.028). After treatment, the expression of TGF-β1 significantly correlated negatively with the expression of CD8
(correlation coefficient = -0.664, P = 0.019).
Conclusions: These results suggested that, in the tumor environment, the change of immune factors after
treatment of cetuximab combined with chemotherapy may be associated with clinical efficacy.
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The mechanism of antitumor immunity is very complex,
involving with various immune cells and their secretory
cytokines [1]. It is well known that antitumor immunity
is mainly mediated by cellular immunology, whereas
humoral immunity (denoting immune responses that are
mediated by antibodies) does not play an important role
in antitumor immunity [2]. In some cases, humoral
immunity plays a positive role in antitumor immunity
[3]. However, humoral immunity can impair specific
immune responses that recognize and attack tumor cells
in some cases, resulting in the proliferation and invasion
of tumor cells [1]. It is reported that humoral immunity
can also induce immune response, and can enhance the
effect of immune response to tumor specific antigens,
when combined with other therapeutic approaches [2].
Thus, the immunomodulatory effect of humoral immunity
(antibodies) remains controversial.
Cetuximab (Erbitux, C225) is an anti-EGFR (epidermal
growth factor receptor) antibody used for the treatment
of metastatic colorectal cancer and head and neck
cancer [4]. Cetuximab is a chimeric (mouse/human)
monoclonal antibody given by intravenous infusion that is
manufactured and distributed by the drug companies
Bristol-Myers Squibb and Eli Lilly and Company. When
combined with radiotherapy and chemotherapy, cetuximab
has shown synergistic and potential antitumor activity in
many cancers [5]. The antitumor mechanism of cetuximab
is complex, consisting of blockade of the cell signaling that
contributes to cell proliferation, antibody-dependent
cellular cytotoxicity (ADCC), and complement-dependent
cytotoxicity (CDC) [6]. At present, there have been few
reports about the immunomodulatory effect of antibodies,
except ADCC and CDC [7]. On the contrary, there
have been many studies about the immunomodulatory
effects (immunosuppressive effects) of chemotherapy [8].
Chemotherapy is currently believed to inhibit the cellular
immunity, reflecting by the observed situation in clinic that
the more the cycle of chemotherapy is, the more severe the
immunosuppressive effect is [9]. Slovin showed that the
immune state could return to normal levels in patients
whose lesion relieved after chemotherapy, whereas the
immune state could not return to normal levels in
patients whose lesion did not relieve after chemotherapy
[8]. Recently, several reports indicated that the original
immune state is closely associated with the prognosis of
cancer patients [10,11]. However, the effect of chemother-
apy combined with monoclonal antibodies (mAbs) on
the immune state of the tumor environment remains
unclear and controversial. Furthermore, the effect of
the immune state on the clinical efficacy of cancer patients
also remains unclear.
In this study, 12 patients with colorectal cancer, who
received the treatment of chemotherapy combined withC225, were enrolled in this study. The tumor specimen of
the primary colorectal cancer before and after treatment
was obtained. The expression of a series of immune factors
(TGF-β1, CD8, IL-2, TNF-α, and VEGF) was measured by
immunochemistry. The aim of this study is to examine the
effect of chemotherapy combined with cetuximab on
the immune state of the tumor environment, and the
correlation of that effect and clinical efficacy.Methods
Patients and specimen
Twelve patients (11 men and 1 woman) with colorectal
cancer, who received the treatment of chemotherapy com-
bined with C225 in the Department of Medical Oncology
of Chinese PLA General Hospital (Beijing, China) during
the 2-year period from December 2010 to June 2012, were
enrolled in this study. The age of patients ranged from 21
to 60 years, with a mean age of 47.5 years. All the patients
had an Eastern Cooperative Oncology Group (ECOG)
performance status of 0-1. The general clinicopathological
characteristics of patients were shown in Table 1.
The criteria for inclusion in this study were: age ≥18
years; ECOG performance status ≤2; tumors were
demonstrated as colorectal cancer by pathology, and did
not receive the therapy of mAbs; at least one measurable
tumor lesion, demonstrated by CT or MRI; an expected
surviving period ≥3 months; routine blood tests performed
0-3 days before chemotherapy (absolute neutrophil ≥1.5 ×
109/L, platelets ≥100 × 109/L, and hemoglobin ≥10 g/dL);
hepatic function test (aspartate aminotransaminase and
alanine aminotransferase should be <1.5-fold of the upper
limit of normal values, and they should be <2.5-fold of the
upper limit of normal values in patients with known hepatic
metastases); renal function test (a calculated creatinine
clearance rate was <45 mL/min).
The criteria for exclusion in this study were: brain
metastasis; receiving the therapy of mAbs; local therapy in
the tumor lesion; severe allergic reactions; no measurable
tumor lesions; an expected survival period <3 months.
This study was conducted according to the International
Conference on Harmonisation (ICH) Good Clinical
Practice guidelines, including obtaining written informed
consent from all patients.Experimental procedure
Twelve patients with colorectal cancer, who received the
treatment of chemotherapy combined with C225, were
enrolled in this study. The tumor specimen of the
primary colorectal cancer before and after treatment
was obtained by surgery or puncture. Informed consent
was obtained from all patients. After fixation by 10%
formaldehyde, the tumor specimen was embedded in
paraffin and cut into 4-μm serial sections.
Table 1 General and clinicopathological characteristics of patients (n = 12)
Patient no. Sex Diagnosis Regimen Treatment number Clinical efficacy
1 Male Colon cancer metastases to liver C225 + FOLFIRI 3 PD
2 Male Rectal cancer metastases to liver C225 + CPT-11 3 PD
3 Male Rectal cancer metastases to liver C225 + FOLFOX 2 PD
4 Male Rectal cancer metastases to LN C225 + FOLFIRI 3 PD
5 Male Colon cancer metastases to liver C225 + XELOX 4 SD
6 Male Rectal cancer metastases to liver C225 + CPT-11 18 PR
7 Male Rectal cancer metastases to liver C225 + FOLFOX 5 PR
8 Male Rectal cancer metastases to liver C225 + FOLFOX 1 PR
9 Male Colon cancer metastases to liver C225 + FOLFOX 12 PR
10 Male Colon cancer metastases to liver C225 + FOLFOX 12 PR
11 Male Colon cancer metastases to liver C225 + FOLFIRI 3 PR
12 Female Colon cancer metastases to liver C225 + FOLFIRI 3 PR
CPT-11, Irinotecan; FOLFIRI, Irinotecan + 5-fluorouracil + calcium folinate; FOLFOX, oxaliplatin + 5-fluorouracil + calcium folinate; LN, lymph nodes; PD, Progressive
Disease; PR, Partial Response; SD, Stable Disease; XELOX, oxaliplatin + capecitabine.
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The expression of TGF-β1, CD8, IL-2, TNF-α, and VEGF
was detected by an immunohistochemistry StreptAvidin-
Biotin Complex (SABC) method. Briefly, the sections were
deparaffinized, hydrated to water, and incubated with
3% H2O2 for 30 min at room temperature to eliminate
endogenous peroxidase. After rinsing with distilled water
and immersion in phosphate buffered saline (PBS), the
sections were submitted to antigen retrieval by a microwave
oven in citrate buffer (pH 6.0). Ten percent of goat serum
was used to eliminate non-specific staining. The sections
were incubated with the primary antibody overnight at 4°C
and for an additional 45 min at 37°C. Primary antibodies
consist of four antibodies: goat anti-human TGF-β1, CD8,
IL-2, TGF-β1, or VEGF mAbs (Zhongshan Goldenbridge














1 ++ +++ Increase 3 PD
2 + ++ Increase 3 PD
3 + ++ Increase 2 PD
4 + ++ Increase 3 PD
5 ++ ++ Stable 4 SD
6 +++ +++ Stable 18 PR
7 +++ - Decrease 5 PR
8 - + Increase 1 PR
9 ++ ++ Stable 12 PR
10 + +++ Increase 12 PR
11 +++ +++ Stable 3 PR
12 + + Stable 3 PRthen incubated with a biotinylated secondary antibody
(Zhongshan Goldenbridge Biotechnology Co., Beijing, China)
for 20 min at 37°C and then horseradish peroxidase
(HRP)-labeled SABC for 15 min before addition of
3,3’-diaminobenzidine (DAB). Finally, the stained slides
were counterstained with Hematoxylin and Eosin (HE),
dehydrated, made transparent, and sealed. In the negative
controls in which the primary antibody was omitted, there
was no staining. Evaluation of the staining results was
according to the traditional semi-quantitative grading
method and judgments were independently made by two
experienced pathologists through a single-blind method.
According to Beesley’s immune grading method, 10 fields
were randomly chosen at a ×400 magnification. For
TGF-β1, CD8, IL-2, TNF-α, and VEGF, grading was
determined according to the percentage of positive
cell and staining intensity: a percentage of positive
cells <5% or a light yellow staining was considered as (-); a
percentage of positive cells between approximately 5% and
25% with brown yellow granules was considered as (+); a
percentage of positive cells between approximately 26%
and 50% with brown yellow granules was considered
as (++); and a percentage of positive cells >55% with
dark brown granules was considered as (+++).
Response Evaluation Criteria in Solid Tumors (RECIST)
The clinical evaluation of the patients who all had measur-
able target lesions was performed according to the RECIST
proposed by NCI and et al. [12], which was described as
following: Complete Response (CR): disappearance of all
target lesions; Partial Response (PR): at least a 30% decrease
in the sum of the longest diameter (LD) of target lesions,
taking as reference the baseline sum LD; Stable Disease
(SD): neither sufficient shrinkage to qualify for PR nor suffi-
cient increase to qualify for PD, taking as reference the
Table 3 The correlation of the change of TGF-β1





Decrease 0 1 1
Stable 0 5 5
Increase 4 2 6
Summary 4 8 12
PD, SD, PR and CR were transformed to two categorical variables (invalid
(defined as 0, including PD) and clinically beneficial (defined as 1, including
SD, PR, and CR)).
The number of patients was calculated.
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Disease (PD): at least a 20% increase in the sum of the LD
of target lesions, taking as reference the smallest sum LD
recorded since the treatment started or the appearance of
one or more new lesions.
Statistical analysis
All data in this study were processed using SPSS 13.0 soft-
ware. The data were pretreated as follows: the staining in-
tensity (-), (+), (++), and (+++) were transformed to 0, 1, 2,
and 3, respectively. In the correlation analysis, PD was
transformed to 1, SD was transformed to 2, and PR and CR
were transformed to 3. In other analyses, PD, SD, PR,
and CR were transformed to two categorical variables
(invalid (defined as 0, including PD) and clinicallyTable 4 The correlation of change of expression of immune fa
examined by the Spearman’s correlation analysis
Treatment number
Clinical efficacy Correlation coefficient 0.479
P value 0.115
Sample size 12
CD8 Correlation coefficient 0.027
P value 0.935
Sample size 12
IL-2 Correlation coefficient −0.585
P value 0.046a
Sample size 12
VEGF Correlation coefficient 0.171
P value 0.594
Sample size 12
TNF-α Correlation coefficient 0.048
P value 0.883
Sample size 12
TGF-β Correlation coefficient −0.527
P value 0.078
Sample size 12
aP <0.05.beneficial (defined as 1, including SD, PR and CR)).
For group comparisons, unordered categorical variables
were compared using chi-square (χ2) test or Fisher’s exact
test. The expression of these immune factors before and
after treatment was compared by the Wilcoxon signed-
rank test. The Spearman correlation was used to measure
the linear relationship between two datasets. A P value
≤0.05 was considered statistically significant.
Results
The general and clinicopathological characteristics of the
12 patients were shown in Table 1. As shown in Table 2, six
of 12 patients (50%) showed increase in the expression of
TGF-β after treatment, five of 12 patients (42%) showed no
change (stable), and only one patient (8%) showed decrease.
In the six patients who showed increase in the expression
of TGF-β after treatment, four showed PD and two showed
PR. In the five patients who showed no change, four
showed PR and one showed SD. After statistical analysis
(Table 3), there was no significant difference between the
expression of TGF-β1 before and after the treatment
(Wilcoxon signed-rank tests, P >0.05). The change of
TGF-β1 expression after treatment significantly correlated
negatively with clinical efficacy (Chi-square tests, χ2 = 6.000,
P = 0.05). One hundred percent (1/1) of the patients were
clinically beneficial when the expression of TGF-β1 de-
creased, whereas 33.33% (2/6) of the patients were clinically
beneficial when the expression of TGF-β1 increased.ctors, clinical efficacy, and treatment number was










−0.112 0.391 0.000 0.050
0.729 0.208 1.000 0.878
12 12 12 12
−0.684 −0.114 0.218 0.184 0.361
0.014a 0.724 0.496 0.568 0.249
12 12 12 12 12
Table 5 The correlation of expression of immune factors and clinical efficacy before treatment was examined by the
Spearman’s correlation analysis
Clinical efficacy CD8 IL-2 VEGF TNF-α
CD8 Correlation coefficient −0.116
P value 0.719
Sample size 12
IL-2 Correlation coefficient 0.093 0.117
P value 0.774 0.717
Sample size 12 12
VEGF Correlation coefficient 0.090 0.213 −0.265
P value 0.781 0.507 0.405
Sample size 12 12 12
TNF-α Correlation coefficient 0.131 0.055 0.629 0.130
P value 0.684 0.866 0.028a 0.688
Sample size 12 12 12 12
TGF-β Correlation coefficient 0.277 −0.413 0.312 −0.519 0.257
P value 0.383 0.182 0.323 0.084 0.420
Sample size 12 12 12 12 12
aP <0.05.
Table 6 The correlation of the expression of immune
factors after treatment was examined by the Spearman’s
correlation analysis
CD8 IL-2 VEGF TNF-α
IL-2 Correlation coefficient −0.138
P value 0.669
Sample size 12
VEGF Correlation coefficient 0.173 0.252
P value 0.592 0.429
Sample size 12 12
TNF-α Correlation coefficient 0.270 0.004 0.153
P value 0.396 0.989 0.634
Sample size 12 12 12
TGF-β Correlation coefficient −0.664a 0.074 −0.167 0.113
P value 0.019 0.820 0.604 0.725
Sample size 12 12 12 12
aP <0.05.
Zhu et al. World Journal of Surgical Oncology 2013, 11:226 Page 5 of 7
http://www.wjso.com/content/11/1/226As for CD8, IL-2, VEGF, and TNF-α, there were no
significant differences between the expression of
these immune factors before and after the treatment
(Wilcoxon signed-rank tests, P >0.05, data not shown).
Furthermore, the change of immune parameter expression
after treatment did not significantly correlate with clinical
efficacy (Chi-square tests, P >0.05, data not shown).
The correlation of the change of immune parameter
expression after treatment (CD8, IL-2, VEGF, TNF-α, and
TGF-β), clinical efficacy and treatment number was exam-
ined by the Spearman’s correlation analysis (Tables 4, 5, 6).
The change of IL-2 expression after treatment significantly
correlated negatively with treatment number (correlation
coefficient = -0.585, P = 0.046). The change of TGF-β1
expression after treatment significantly correlated negatively
with clinical efficacy (correlation coefficient = -0.684,
P = 0.014). Before treatment, the expression of TNF-α
significantly correlated positively with the expression
of IL-2 (correlation coefficient = 0.629, P = 0.028).
After treatment, the expression of TGF-β1 significantly
correlated negatively with the expression of CD8
(correlation coefficient = -0.664, P = 0.019). As for
CD8, VEGF, and TNF-α, the correlation of the change of
immune parameter expression after treatment (CD8, IL-2,
VEGF, TNF-α, and TGF-β), clinical efficacy and treatment
number is not significant (P >0.05).
Discussion
The effect of chemotherapy combined with monoclonal
antibodies (mAbs) on the immune state of the tumor
environment remains unclear and controversial. In thisstudy, we examined the effect of chemotherapy combined
with cetuximab on the immune state of the tumor
environment, and the correlation of that effect and
the clinical efficacy. The results showed that in the
tumor environment, the change of immune factors before
and after the treatment of cetuximab combined with
chemotherapy may be associated with clinical efficacy and
treatment number.
TGF-β, a potent immunosuppressive cytokine that can
inhibit the immune system, can promote the develop-
ment, invasion and metastasis of tumors [13]. TGF-β is
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tumor, TGF-β can inhibit tumor proliferation, whereas
TGF-β can promote the development, invasion, and
metastasis of tumors at the middle or late stage of tumors
[15]. It is generally accepted that inhibition of TGF-β play
a positive role in promoting the antitumor immunity [16].
In this study, the change of TGF-β1 expression after
treatment significantly correlated negatively with clinical
efficacy. One hundred percent (1/1) of the patients were
clinically beneficial when the expression of TGF-β1 de-
creased, whereas 33.33% (2/6) of the patients were clinically
beneficial when the expression of TGF-β1 increased. These
results suggested that TGF-β1 plays a negative role in the
clinical efficacy of patients after the treatment of cetuximab
combined with chemotherapy. We speculate that decreased
expression of TGF-β1 may inhibit the immunosuppressive
state of the patients and promote the antitumor immunity,
whereas increased expression of TGF-β1 possesses the
opposite effect. Thus, inhibition of TGF-β1 may enhance
the therapeutic efficacy of treatment of cetuximab com-
bined with chemotherapy. Our results were consistent with
previous reports that TGF-β antibody or inhibitors could
inhibit the invasion and metastasis of tumors [16].
CD8 is the distinctive marker of cytotoxic T cells, which
are considered to be the main effecter cells in antitumor
immunity [17]. IL-2, also called T cell stimulating cytokine,
is secreted by T cells. IL-2 is the main cytokine that induces
the proliferation of T cells [18]. Also, IL-2 can activate other
killer cells and plays an important role in antitumor
immunity [19]. In this study, there were no significant dif-
ferences between the expression of CD8 and IL-8 before
and after the treatment, indicating that the treatment of
cetuximab combined with chemotherapy did not signifi-
cantly affect the expression of CD8 and IL-8. Our results
are inconsistent with previous reports that chemotherapy is
currently believed to inhibit the cellular immunity [9].
TNF-α is produced by monocytes and macrophages,
and can inhibit the proliferation of tumor cells. There
were no significant differences between the expression
of TNF-α before and after the treatment. Furthermore,
the change of TNF-α expression after treatment did not
significantly correlate with clinical efficacy. The same results
were obtained in VEGF expression. These results indicated
that the expression of TNF-α and VEGF might not be
significantly affected by the treatment of cetuximab com-
bined with chemotherapy, and the change of TNF-α and
VEGF expression after treatment might not significantly
affect the clinical efficacy.
It is reported that cytokines have extensive interaction
and could be regulated by each other [18]. In this study, the
expression of TNF-α significantly correlated positively with
the expression of IL-2 before treatment, indicating that
TNF-α and IL-2 might promote the expression of each
other and additive antitumor activity was achieved. It hasto be noted that, the expression of TGF-β1 significantly
correlated negatively with the expression of CD8 after treat-
ment. The reason may be that TGF-β1 could inhibit the
proliferation of CD8-positive T cells, which is consistent
with previous reports [20].
There are several limitations in this study. First, the
sample size of this study is small (due to the difficult
achievement of tumor specimen before and after treat-
ment). Second, the control groups of a single cetuximab or
chemotherapy lacks. In our further studies, we will enlarge
the sample size of this study and add the control
groups, to obtain more accurate conclusions.
Conclusions
In summary, our study suggested that, in the tumor
environment, the change of immune factors before
and after the treatment of cetuximab combined with
chemotherapy may be associated with clinical efficacy.
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